AP4 promotes HCC cell proliferation, migration and invasion and reduces chemotherapy sensitivity via LAPTM4B by activating the phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) signalling pathway and caspase‐dependent pathway. The gene discussed is LAPTM4B; the disease is hepatocellular carcinoma.